New cocktail of old drugs takes on advanced cancers

NCT ID NCT07671534

Recruiting now Disease control Sponsor: Sarcoma Oncology Research Center, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improve survival. The study plans to enroll 60 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine, mitomycin C, and thalidomide
What this could lead to: If successful, this could offer a new treatment option for people with advanced solid tumors who have already tried other therapies.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 60 participants, so results may not apply to everyone. The drugs can cause side effects like low blood counts, fatigue, and nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR CANCER

Contacts and locations

Locations

Sarcoma Oncology Research Center / Cancer Center of Southern California
RECRUITING

Santa Monica, California, 90403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.